2021 to 2022 Saw 3 Percent Increase in Infant Mortality Rate in U.S.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Nov. 1, 2023 -- From 2021 to 2022, there was a 3 percent increase in the infant mortality rate in the United States, according to a November Vital Statistics Rapid Release report, a publication from the U.S. Centers for Disease Control and Prevention.
Danielle M. Ely, Ph.D., and Anne K. Driscoll, Ph.D., from the National Center for Health Statistics in Hyattsville, Maryland, used U.S. linked birth/infant death files to present provisional 2022 data on infant mortality rates.
The researchers found that in 2022, the provisional infant mortality rate for the United States was 5.60 infant deaths per 1,000 live births, which was 3 percent higher than the rate of 5.44 in 2021. From 2021 to 2022, there was a 3 percent increase in the neonatal mortality rate (from 3.49 to 3.58) and a 4 percent increase in the postneonatal mortality rate (from 1.95 to 2.02). Among infants of American Indian and Alaska Native non-Hispanic and White non-Hispanic women, mortality rates increased significantly (7.46 to 9.06 and 4.36 to 4.52, respectively). Infant mortality rates increased significantly for infants of women ages 25 to 29 years, from 5.15 in 2021 to 5.37 in 2020. Mortality rates also increased significantly for total preterm and early preterm infants, for male infants, and in four states (Georgia, Iowa, Missouri, and Texas). For two of the 10 leading causes of death (maternal complications and bacterial sepsis), mortality rates increased.
"Although not statistically significant, rates generally increased for most other race and Hispanic origin, maternal age, and gestational age groups, as well as for female infants, in a majority of states, and for three of the 10 leading causes of death," the authors write.
Source: HealthDay
Posted : 2023-11-02 06:52
Read more
- Psychologists ID Financial, Administrative Barriers to Accepting Insurance
- Recommendations Provided for Treating, Preventing HIV
- FDA Says Shortage of GLP-1 Tirzepatide (Mounjaro, Zepbound) Is Over
- Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia
- Salmonella Outbreak Triggers Recall of Cucumbers in 26 States
- Upadacitinib Improves Ulcerative Colitis Outcomes at 12 Months
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions